Home › Tetragenetics Launches Partnership Program For Discovery And Development Of Therapeutic Monoclonal Antibodies
 

Keywords :   


Tetragenetics Launches Partnership Program For Discovery And Development Of Therapeutic Monoclonal Antibodies

2016-01-06 06:05:47| drugdiscoveryonline Home Page

Tetragenetics Inc., an emerging biotechnology company engaged in the expression of ion channel drug targets, announced recently a new partnership program for the discovery and development of therapeutic monoclonal antibodies (mAbs) directed against well-known ion channel drug targets implicated in a wide range of disease states –such as pain and autoimmune disorders

Tags: development program partnership discovery

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.05OnPrintShop to showcase web-to-print capabilities at drupa
08.05Grafotronic announces Benelux DCL installation
08.05Onoxa Unveils First Line of Men\'s Grooming Products
08.05Edgewell Announces Fiscal Q2 Results
08.05Zuiko Finalizes Agreement to Acquire Delta
08.05NAD Recommends Unilever Discontinue or Modify Certain Antiperspirant Claims
08.05Verb Products Reformulates Curl Collection and Introduces New Curl Defining Mask
08.05Mitsui Chemicals Asahi Life Materials Develops Compostable Plastic
More »